Celltrion said on the 11th that it has launched the liquid formulation of its autoimmune disease treatment Remsima (ingredient name Infliximab) in Europe.
According to Celltrion, the company recently won contracts in national tenders for Infliximab in Denmark and Norway with the Remsima intravenous (IV) liquid formulation. After receiving European approval for the Remsima IV liquid formulation in Nov. last year, the company prepared product supply to compete in major national tenders.
In Norway, sales began immediately after the award, and under the contract the product will be supplied through Jan. 2028. Celltrion expects this to secure about a 35% share in Norway's Infliximab IV market.
The Remsima liquid formulation is an addition to the existing Remsima IV (100 mg lyophilized formulation) and subcutaneous (SC) formulations. It reflects demand in European clinical settings for a multi-dose liquid formulation that can improve storage and handling efficiency and simplify compounding.
Compared with the lyophilized formulation, the liquid formulation can cut preparation time by about 50%, and it is known to reduce labor and consumable expense during dose preparation by about 20%. The company said storage space and storage costs can also be reduced by up to 70%, helping improve operational efficiency for medical institutions.
Celltrion has also secured patents related to the Remsima liquid formulation. Patent registrations have been completed in most countries, including the five major European markets (EU5) such as the United Kingdom, Germany and France. Celltrion is currently the only company selling a liquid formulation of Infliximab.
With this liquid launch, Celltrion has built a full lineup covering Infliximab IV (lyophilized and liquid) and SC formulations. Based on this, the company plans to pursue both expanded Remsima prescriptions and improved profitability in the European market.
Starting in Northern Europe, the company plans to expand the Remsima liquid rollout to major European countries including France, the Netherlands and the Czech Republic. According to IQVIA, as of the third quarter of last year, the Remsima portfolio (IV and SC) holds the No. 1 prescription share in Europe's Infliximab market at about 68%.
Baek Seung-du, head of Celltrion's Northern Europe office, said, "The Remsima liquid formulation was developed to meet the needs of clinical settings and won tenders immediately after launch," and added, "We will continue to expand the market to provide diverse treatment options for local healthcare professionals and patients."